Trials / Completed
CompletedNCT01802138
A Pilot Study of Activated T Cell Therapy for Refractory/Relapsed Neuroblastoma
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 6 (estimated)
- Sponsor
- Seoul National University Hospital · Academic / Other
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
Activated T cell were manufactured through in vitro T cell expansion of autologous T cell. We designed this study to determine the feasibility and safety of Activated T-lymphocyte cell therapy for refractory/relapsed neuroblastoma patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Activated T lymphocyte | intravenous dripping of 200 ml (10\^9\~2\*10\^10 lymphocytes) for 1 hour. |
Timeline
- Start date
- 2013-02-01
- Primary completion
- 2016-06-01
- Completion
- 2018-10-31
- First posted
- 2013-03-01
- Last updated
- 2019-04-09
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01802138. Inclusion in this directory is not an endorsement.